| Source | Treatment | Randomized no. | % male | Mean age | % current smokers | % severe or very severe | FEV₁ | FVC | BDI | SGRQ |
| :------------------ | :---------- | :------------- | :----- | :------- | :---------------- | :---------------------- | :---------- | :------- | :------- | :---------- |
| B2336; non-ICS²⁷    | Placebo     | 187            | 81%    | 65       | 44%               | 39%                     | 1.37 (0.50) | 2.60 (0.78) | 6.7 (2.0) | 42.5 (18.3) |
|                     | IND 150     | 173            | 74%    | 63       | 51%               | 38%                     | 1.36 (0.52) | 2.56 (0.88) | 6.9 (2.0) | 42.1 (19.3) |
| B2346; non-ICS²⁸    | Placebo     | 125            | 55%    | 64       | 55%               | 34%                     | 1.37 (0.58) | NR       | NR       | 48.0 (17.3) |
|                     | IND 150     | 144            | 51%    | 62       | 58%               | 40%                     | 1.39 (0.60) | NR       | NR       | 49.2 (20.2) |
| B2333; non-ICS²⁹    | Placebo     | 113            | 94%    | 64       | 27%               | 53%                     | 1.15 (0.39) | 2.68 (0.67) | 6.5 (2.2) | 41.9 (19.6) |
|                     | IND 150     | 116            | 94%    | 65       | 27%               | 50%                     | 1.11 (0.37) | 2.64 (0.66) | 6.4 (2.3) | 41.8 (18.1) |
|                     | IND 300     | 112            | 97%    | 65       | 25%               | 46%                     | 1.16 (0.37) | 2.70 (0.64) | 6.7 (2.1) | 42.2 (16.9) |
| BI 302²⁹; non-ICS²⁹ | Placebo     | 76             | 94%    | 67       | 27%               | 35%                     | 1.20 (0.41) | 2.67 (0.7) | 7.4 (2.5) | 38.6 (17.7) |
|                     | IND 150     | 85             | 96%    | 67       | 34%               | 31%                     | 1.31 (0.45) | 2.70 (0.66) | 7.5 (2.1) | 37.8 (18.3) |
|                     | IND 300     | 87             | 97%    | 67       | 36%               | 33%                     | 1.22 (0.41) | 2.61 (0.68) | 7.8 (2.4) | 35.5 (16.2) |

Table 5 Results of network meta-analysis: indacaterol 150 μg versus alternatives without covariates

| | Trough FEV₁, L at 12 weeks | Trough FEV₁, L at 6 months | SGRQ total score at 6 months | TDI total score at 6 months |
| :----------------------- | :----------------------------- | :----------------------------- | :----------------------------- | :----------------------------- |
| | Difference in CFB (95% CrI) | Prob of IND 150 being better | Difference in CFB (95% CrI) | Prob of IND 150 being better | Difference in CFB (95% CrI) | Prob of IND 150 being better | Difference in CFB (95% CrI) | Prob of IND 150 being better |
| **All studies** | | | | | | | | |
| SAL/FP 50/500 μg         | 0.03 (0.00, 0.06)              | 99%                          | 0.01 (-0.04, 0.05)             | 61%                          | -2.16 (-4.96, 0.95)            | 92%                          | -0.69 (-1.38, 0.01)            | 3%                           |
| SAL/FP 50/250 μg         | 0.02 (-0.04, 0.08)             | 72%                          | 0.00 (-0.07, 0.07)             | 51%                          | NR                           | NR                           | 0.21 (-0.57, 0.99)             | 70%                          |
| FOR/BUD 9/320 μg         | 0.09 (0.06, 0.11)              | >99%                         | 0.08 (0.05, 0.12)              | >99%                         | -0.39 (-3.69, 2.92)            | 60%                          | NR                           | NR                           |
| FOR/BUD 9/160 μg         | 0.11 (0.08, 0.13)              | >99%                         | 0.10 (0.06, 0.14)              | >99%                         | -1.48 (-5.51, 2.61)            | 78%                          | NR                           | NR                           |
| **All studies excluding 3 Asian studies** | | | | | | | | |
| SAL/FP 50/500 μg         | 0.04 (0.01, 0.08)              | 99%                          | 0.02 (-0.02, 0.07)             | 88%                          | -3.45 (-6.64, -0.39)           | 98%                          | -0.60 (-1.34, 0.14)            | 6%                           |
| SAL/FP 50/250 μg         | 0.03 (-0.04, 0.09)             | 80%                          | 0.01 (-0.06, 0.08)             | 66%                          | NR                           | NR                           | 0.30 (-0.51, 1.11)             | 76%                          |
| FOR/BUD 9/320 μg         | 0.10 (0.06, 0.13)              | >99%                         | 0.10 (0.05, 0.14)              | >99%                         | -0.86 (-4.20, 2.41)            | 71%                          | NR                           | NR                           |
| FOR/BUD 9/160 μg         | 0.12 (0.08, 0.15)              | >99%                         | 0.12 (0.07, 0.16)              | >99%                         | -1.92 (-5.88, 2.00)            | 85%                          | NR                           | NR                           |

Abbreviations: CFB, change from baseline; CrI, 95% credibility interval; FEV₁, forced expiratory volume in 1 second; FOR/BUD, fixed-dose formoterol and budesonide; IND, indacaterol; NR, not reported; Prob, probability; SAL/FP, fixed-dose salmeterol and fluticasone propionate; SGRQ, St. George's Respiratory Questionnaire; TDI, Transition Dyspnea Index.

Table 6 Results of network meta-analysis: indacaterol 300 μg versus alternatives without covariates

| | Trough FEV₁, L at 12 weeks | Trough FEV₁, L at 6 months | SGRQ total score at 6 months | TDI total score at 6 months |
| :----------------------- | :----------------------------- | :----------------------------- | :----------------------------- | :----------------------------- |
| | Difference in CFB (95% CrI) | Prob of IND 300 being better | Difference in CFB (95% CrI) | Prob of IND 300 being better | Difference in CFB (95% CrI) | Prob of IND 300 being better | Difference in CFB (95% CrI) | Prob of IND 300 being better |
| **All studies** | | | | | | | | |
| SAL/FP 50/500 μg         | 0.03 (0.00, 0.06)              | 97%                          | 0.01 (-0.04, 0.05)             | 63%                          | -0.74 (-3.56, 2.28)            | 70%                          | -0.51 (-1.19, 0.17)            | 8%                           |
| SAL/FP 50/250 μg         | 0.02 (-0.05, 0.08)             | 70%                          | 0.00 (-0.07, 0.07)             | 52%                          | NR                           | NR                           | 0.39 (-0.39, 1.17)             | 84%                          |
| FOR/BUD 9/320 μg         | 0.08 (0.06, 0.11)              | >99%                         | 0.08 (0.05, 0.12)              | >99%                         | 1.02 (-2.30, 4.28)             | 26%                          | NR                           | NR                           |
| FOR/BUD 9/160 μg         | 0.10 (0.08, 0.13)              | >99%                         | 0.10 (0.06, 0.14)              | >99%                         | -0.06 (-4.12, 3.96)            | 51%                          | NR                           | NR                           |
| **All studies excluding 3 Asian studies** | | | | | | | | |
| SAL/FP 50/500 μg         | 0.03 (-0.01, 0.07)             | 95%                          | 0.02 (-0.03, 0.06)             | 76%                          | -1.76 (-4.99, 1.26)            | 89%                          | -0.45 (-1.18, 0.29)            | 12%                          |
| SAL/FP 50/250 μg         | 0.02 (-0.05, 0.08)             | 70%                          | 0.01 (-0.06, 0.08)             | 61%                          | NR                           | NR                           | 0.46 (-0.35, 1.27)             | 86%                          |
| FOR/BUD 9/320 μg         | 0.09 (0.05, 0.12)              | >99%                         | 0.09 (0.05, 0.13)              | >99%                         | 0.81 (-2.50, 4.05)             | 30%                          | NR                           | NR                           |
| FOR/BUD 9/160 μg         | 0.11 (0.07, 0.14)              | >99%                         | 0.11 (0.06, 0.15)              | >99%                         | -0.23 (-4.21, 3.60)            | 55%                          | NR                           | NR                           |

Abbreviations: CFB, change from baseline; CrI, 95% credibility interval; FEV₁, forced expiratory volume in 1 second; FOR/BUD, fixed-dose formoterol and budesonide; IND, indacaterol; NR, not reported; Prob, probability; SAL/FP, fixed-dose salmeterol and fluticasone propionate; SGRQ, St. George's Respiratory Questionnaire; TDI, Transition Dyspnea Index.

8) 다군 환자에서 흡입지속성항콜린제 또는 흡입24시간지속성베타-2작용제를 사용하거나 ICS/LABA 복합제를 사용하는 중에도 급성 악화를 경험하거나 mMRC 2단계 이상의 호흡곤란이 지속되는 경우 환자의 증상 호전 여부와 부작용 발생 유무를 관찰하면서 기존의 여러 약제를 병합하여 사용할 수 있다. 흡입지속성항콜린제와 흡입지속성베타-2작용제(흡입24시간지속성 베타-2작용제 포함)를 병용요법하거나, ICS/LABA 복합제에 흡입지속성항콜린제를 추가하여 사용할 수 있다(근거수준: 낮음, 권고강도: 강함).

근거표 8-1: ICS/LABA + LAMA vs ICS/LABA

| 연구수 | 연구설계 | 비뚤림 위험 | 비일관성 | 비직접성 | 비정밀 | 출판 비뚤림 | 근거수준 |
| :----- | :------- | :---------- | :------- | :------- | :----- | :---------- | :------- |
| 1      | 사후분석 | 없음        | 있음     | 없음     | 없음   | 없음        | 중등도   |

<PAGE>117